Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × OTHER × bempegaldesleukin × Clear all

Phase

Phase 2 2 Phase 1 1

Status

Sponsor Class

INDUSTRY 3 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

Cyclophosphamide 378 Radiotherapy 253 fludarabine 210 Gemcitabine 192 Cisplatin 186 Nivolumab 165 pembrolizumab 164 Paclitaxel 159 Carboplatin 148 Magnetic Resonance Spectroscopy 146 fludarabine phosphate 141 Irinotecan 121 Bevacizumab 119 Temozolomide 116 Cytarabine 114 Capecitabine 111 Radiosurgery 107 Specimen Handling 106 Radiation 104 Docetaxel 102 Oxaliplatin 100 Etoposide 100 Biopsy 100 Fluorouracil 99 Rituximab 98 Dexamethasone 98 Ipilimumab 97 Sorafenib 89 Lenalidomide 89 Filgrastim 88

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

43 enrolled 19 charts

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡